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Abstract We demonstrate the mechanism by which Cordyceps
sinensis (CS) mycelium regulates Leydig cell steroidogenesis.
Mouse Leydig cells were treated with forskolin, H89, phorbol
12-myristate 13-acetate, staurosporine, or steroidogenic enzyme
precursors with or without 3 mg/ml CS; then testosterone pro-
duction was determined. H89, but not phorbol 12-myristate
13-acetate or staurosporine, decreased CS-treated Leydig cell
steroidogenesis. CS inhibited Leydig cell steroidogenesis by sup-
pressing the activity of P450scc enzyme, but not 3L-hydroxy-
steroid dehydrogenase, 17K-hydroxylase, 20K-hydroxylase, or
17L-hydroxysteroid dehydrogenase enzymes. Thus, CS activated
the cAMP^protein kinase A signal pathway, but not protein
kinase C, and attenuated P45scc enzyme activity to reduce hu-
man chorionic gonadotropin-stimulated steroidogenesis in puri-
¢ed mouse Leydig cells.
4 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
In the male reproductive system, luteinizing hormone (LH)
will associate with the receptors on Leydig cells to activate
adenylate cyclase through G proteins. The activation results in
an increase of intracellular cAMP, which in turn activates
protein kinase (PK) A [1]. PKA will phosphorylate some pro-
teins and/or induce de novo synthesis of proteins [2]. These
proteins will facilitate the transfer of cholesterol into the inner
mitochondrial membrane, where P450scc enzyme converts
cholesterol to pregnenolone [3]. Steroidogenic enzymes in
the smooth endoplasmic reticulum, including 3L-hydroxyste-
roid dehydrogenase (3L-HSD), 17K-hydroxylase, 20K-hydrox-
ylase, and 17L-hydroxysteroid dehydrogenase (17L-HSD), will
then process pregnenolone to testosterone, a hormone neces-
sary for male reproduction [4].
Cordyceps sinensis (CS), a fungal parasite on the larvae of
Lepidoptera, is a time-honored herbal medicine in many East
Asian cultures [5]. Studies have shown its pharmacological
activities, including modulation of immune response [6,7], in-
hibition of tumor growth [8,9], decrease of blood pressure
[10,11], increase of hepatic energy metabolism and blood
£ow [12], improvement of bioenergy in the liver [13], induc-
tion of cell apoptosis [14], and secretion of adrenal hormone
[15]. It has also been shown that CS can enhance reproductive
activity and restore impaired reproductive functions [16]. How
CS regulates Leydig cell steroidogenesis, however, remains
elusive.
We have previously demonstrated that CS alone could stim-
ulate steroid production in both normal and tumor mouse
Leydig cells [17^19]. However, testosterone production with
human chorionic gonadotropin (hCG) treatment was sup-
pressed by CS in puri¢ed normal mouse Leydig cells [19].
In the present study, we examine whether CS exerts direct
action on sites along the PKA or PKC pathways, or on ster-
oidogenic enzymes in normal mouse Leydig cells. Cells were
treated with N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinoli-
nesulfonamide hydrochloride (H89, PKA inhibitor), stauro-
sporine (PKC inhibitor), or phorbol 12-myristate 13-acetate
(PMA, PKC activator) with or without CS to examine
whether CS activated the PKA or PKC signal transduction
pathways. Also, maximal doses of forskolin (stimulator of
adenylate cyclase), 22R-hydroxycholesterol (substrate for
P450scc), pregnenolone (substrate for 3L-HSD), progesterone
(substrate for 17K-hydroxylase), 17K-hydroxyprogesterone
(substrate for 20K-hydroxylase), and androstenedione (sub-
strate for 17L-HSD) were added to cells with or without CS
to determine whether CS a¡ected enzyme activity.
2. Materials and methods
2.1. Chemicals
M199 medium, fetal bovine serum, Dulbecco’s phosphate-bu¡ered
saline, and gentamicin sulfate were purchased from Gibco (Grand
Island, NY, USA). Tissue culture grade sodium bicarbonate, bovine
serum albumin (BSA), HEPES, penicillin, Percoll gradient solution,
streptomycin, L-nicotinamide adenosine dinucleotide, H89, dehydro-
epiandrosterone, nitroblue tetrazolium, testosterone, ether, PMA,
charcoal, forskolin, and staurosporine were purchased from Sigma
Chemical (St. Louis, MO, USA). [3H]Testosterone used for radio-
immunoassay was purchased from DuPont-New England Nuclear
(Boston, MA, USA). Antiserum to testosterone was a kind gift
from Dr. Paulus S. Wang (National Yang Ming University, Taipei,
Taiwan).
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2.2. Animals
Male B6 (C57BL/6NCrj) mice, 5^6 weeks old, were purchased from
National Cheng Kung University Animal Center (Tainan, Taiwan).
B6 mice should be less than 8 weeks old for experiments to exclude
the exposure of Leydig cells to LH. All animals were housed in groups
of four in 29U18U13-cm polyethylene cages. The animal room was
maintained at 22^24‡C under a constant 12-h light/dark cycle. Purina
mouse chow (Ralston-Purina, St. Louis, MO, USA) and water were
always available.
2.3. Leydig cell isolation
Testes were removed from the killed mice and decapsulated in
M199 containing 4 mM NaHCO3, 25 mM HEPES, 0.06 g penicillin,
0.05 g streptomycin and 0.2% BSA, pH 7.35. After decapsulation, the
testes were incubated in a shaking water-bath (120 cycles/min) at 37‡C
in M199 containing 1% BSA and 100 U/ml collagenase (type II;
Worthington Biochemical, Lakewood, NJ, USA) for 10 min. After
incubation, cold M199 was added to stop the action of the collage-
nase. Seminiferous tubules were separated from interstitial cells by
gravity sedimentation. Cells were then collected by centrifugation
(300Ug for 6 min) and resuspended in 2 ml of M199 containing
0.1% BSA. This suspension, which did not contain seminiferous tu-
bules and was composed of interstitial cells, contained 20^30% Leydig
cells. This interstitial cell preparation was layered onto a Percoll gra-
dient and then centrifuged at 800Ug at 4‡C for 20 min. The gradient,
which was preformed by centrifugation at 25 000Ug for 30 min, con-
tained 10 ml of isotonic Percoll solution and 15 ml M199 plus 0.1%
BSA and 25 mM HEPES [20]. A 1-ml fraction of gradient was col-
lected from the top. Mouse Leydig cells were mainly distributed
in fractions 23^25. The total number of cells and the percentage of
3L-HSD-positive cells were determined in this Leydig cell preparation
[20]. The purity of the Leydig cells was 80^85%.
2.4. Cell culture
Cells were maintained at 37‡C in a humidi¢ed environment con-
taining 95% air and 5% CO2 for all of the following experiments.
Approximately 5U104 cells/100 Wl M199 were plated into each well
of 96-well plates. After 2 h, cells were washed twice with medium
without any serum and then treated with 3 mg/ml CS with or without
various reagents for 3 h. At the end of the incubation, the media were
withdrawn and testosterone levels were determined by radioimmuno-
assay [19].
2.5. Radioimmunoassay
Media from cultures with di¡erent treatments were collected and
diluted with medium to fall within the standard curves for the respec-
tive assays. Twenty-¢ve Wl of diluted sample was withdrawn into a
glass tube and 100 Wl each of testosterone antiserum and
[3H]testosterone were added. An equilibrium reaction occurred at
room temperature for 2 h and was stopped by putting the tubes in
ice. Charcoal was added and incubated for 15 min at 4‡C and then
centrifuged for 10 min to spin down the charcoal bound with free
[3H]testosterone. The supernatant was poured into 3 ml of scintilla-
tion £uid and samples were counted in a L-counter for 2 min [19,21].
2.6. Statistical analysis
Each data point in the ¢gures represents the meanQS.E.M. of
testosterone production in three separate experiments with triplicates
of each treatment. Statistically signi¢cant di¡erences between treat-
ments and controls were determined by one-way ANOVA and the
Fisher PLSD multiple comparison procedure. Statistical signi¢cance
was set at P6 0.05.
3. Results
3.1. The e¡ects of CS with forskolin treatment on testosterone
production in mouse Leydig cells
To determine whether CS a¡ects the cAMP^PKA signal
transduction pathway in mouse Leydig cells, an optimal con-
centration (100 WM) of forskolin was added with or without
CS (3 mg/ml) for 3 h (Fig. 1). CS treated with forskolin sig-
ni¢cantly reduced testosterone production (P6 0.05). The
suppressive e¡ect was about 60%, which indicates that CS
might directly in£uence the cAMP^PKA signal transduction
pathway to regulate mouse Leydig cell steroidogenesis.
3.2. The e¡ect of CS with H89 treatment on testosterone
production in mouse Leydig cells
To further con¢rm whether CS a¡ects the cAMP^PKA
signal transduction pathway in mouse Leydig cells, an optimal
concentration (50 WM) of H89, a PKA inhibitor, was added
Fig. 1. E¡ects of CS with forskolin treatment on testosterone pro-
duction in mouse Leydig cells. Cells were stimulated with a maximal
concentration of forskolin (100 WM) with or without CS (3 mg/ml)
for 3 h. Di¡erent letters above the bars indicate signi¢cant di¡eren-
ces.
Fig. 2. E¡ects of CS with H89 treatment on testosterone production
in mouse Leydig cells. Cells were stimulated with maximal concen-
trations of H89 (50 WM) with or without CS (3 mg/ml) for 3 h. Dif-
ferent letters above the bars indicate signi¢cant di¡erences.
Fig. 3. E¡ects of CS with PMA or staurosporine treatments on tes-
tosterone production in mouse Leydig cells. Cells were stimulated
with maximal concentrations of PMA (2.5 WM), or staurosporine
(10 nM), respectively, with or without CS (3 mg/ml) for 3 h. Di¡er-
ent letters above the bars indicate signi¢cant di¡erences.
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with or without CS (3 mg/ml) for 3 h. Fig. 2 illustrates that
the stimulatory e¡ect of CS on mouse Leydig cell steroido-
genesis was completely blocked by H89 (P6 0.05). This result
strongly suggests that CS activated the PKA pathway to reg-
ulate mouse Leydig cell functions.
3.3. The e¡ect of CS with PMA and staurosporine treatments
on testosterone production in mouse Leydig cells
To determine whether CS activates the PKC signal trans-
duction pathway in mouse Leydig cells, PMA (2.5 WM), a
PKC activator, and staurosporine (10 WM), a PKC inhibitor,
were added separately, with or without CS (3 mg/ml), for 3 h
(Fig. 3). Testosterone production was not reduced with the
treatment of CS plus PMA or staurosporine (Ps 0.05). These
results indicate that CS could not activate the PKC signal
pathway to in£uence steroidogenesis in mouse Leydig cells.
3.4. The e¡ects of CS with 22R-hydroxycholesterol treatment
on testosterone production in mouse Leydig cells
To determine the e¡ect of CS on the activity of P450scc
enzyme in normal mouse Leydig cells, an optimal concentra-
tion (50 WM) of 22R-hydroxycholesterol was added with or
without CS (3 mg/ml) for 3 h (Fig. 4). CS signi¢cantly reduced
testosterone production with the treatment of 22R-hydroxy-
cholesterol (P6 0.05). The suppressive e¡ect was 30%. This
result indicates that CS might have a direct inhibitory e¡ect
on P450scc enzyme.
3.5. The e¡ects of CS with pregnenolone, progesterone, 17K-
hydroxyprogesterone, or androstenedione treatments on
testosterone production in mouse Leydig cells
To determine the e¡ect of CS on 3L-HSD, 17K-hydroxylase,
20K-hydroxylase, and 17L-HSD enzymes on mouse Leydig
cells, pregnenolone (7.95 WM), progesterone (7.95 WM), 17K-
hydroxyprogesterone (7.95 WM), or androstenedione (7.95
WM) were added separately with or without CS (3 mg/ml)
for 3 h. CS did not reduce testosterone production when
combined with pregnenolone (Fig. 5A), progesterone (Fig.
5B), 17K-hydroxyprogesterone (Fig. 5C), or androstenedione
(Fig. 5D) (Ps 0.05). This result indicates that CS has no
e¡ect on 3L-HSD, 17K-hydroxylase, 20K-hydroxylase, or
17L-HSD enzymes in mouse Leydig cells.
4. Discussion
The present study demonstrates that CS activates the PKA
signal transduction pathway, but not the PKC signal path-
way, to regulate steroidogenesis in normal mouse Leydig cells.
In addition, CS directly attenuates P450scc enzyme activity,
but not 3L-HSD, 17K-hydroxylase, 20K-hydroxylase, or 17L-
HSD to suppress hCG- or cAMP-stimulated steroidogenesis
in mouse Leydig cells.
In the present study, H89 completely abolished the e¡ect of
CS on Leydig cell steroidogenesis, which suggests that CS may
stimulate only the cAMP^PKA signal transduction pathway.
It is well known that LH interacts with the receptors on Ley-
Fig. 4. E¡ects of CS with 22R-hydroxycholesterol treatment on tes-
tosterone production in mouse Leydig cells. Cells were stimulated
with a maximal concentration of 22R-hydroxycholesterol (50 WM)
in the absence of presence of CS (3 mg/ml) for 3 h. Di¡erent letters
above the bars indicate signi¢cant di¡erences.
Fig. 5. E¡ects of CS with pregnenolone, progesterone, 17K-hydroxy-
progesterone, or androstenedione treatments on testosterone produc-
tion in mouse Leydig cells. Cells were stimulated with maximal con-
centrations of pregnenolone (A), progesterone (B), 17K-hydroxypro-
gesterone (C), or androstenedione (D) with or without CS (3 mg/
ml) for 3 h. Di¡erent letters above the bars indicate signi¢cant dif-
ferences.
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dig cells to activate adenylate cyclase through G proteins and
that intracellular cAMP will increase to further activate PKA
[1]. PKA will phosphorylate proteins and induce de novo syn-
thesis of proteins to facilitate steroidogenesis [2,3]. Thus, that
CS regulates cAMP^PKA signal transduction for steroidogen-
esis in mouse Leydig cells is not extraordinary. Moreover, in
the present study, PKC activator or inhibitor did not a¡ect
testosterone production in the presence of CS, which demon-
strates that the PKC pathway was not involved. Although it
has been shown that the PKC pathway may also play some
roles in steroidogenesis [22,23], it is clear that CS induced only
the cAMP^PKA signal transduction pathway, but not the
PKC pathway, to regulate mouse Leydig cell steroidogenesis
in the present study.
Some studies have shown that many factors can inhibit the
activities or expression of steroidogenic enzymes such as
P450scc, 3L-HSD, 17K-hydroxylase, 20K-hydroxylase, and
17L-HSD, and that this inhibition correlates with the low
production of testosterone by Leydig cells [24^26]. CS might
have adverse e¡ects on one or more of these enzymes, thereby
reducing testosterone production in mouse Leydig cells. In the
present study, CS signi¢cantly suppressed the activity of
P450scc enzyme in Leydig cells, which correlated with the
low production of testosterone in the presence of a testoster-
one production stimulator. In addition to suppressing the ac-
tivity of P450scc, it is also possible that CS might similarly
a¡ect the expression of other steroidogenic enzymes and,
therefore, steroidogenesis, which has been shown in many
studies [27^29]. Indeed, CS reduced the activity of P450scc
enzyme only by about 30%, which was not consistent with
the 60% inhibition with forskolin treatment in the present
study or with hCG treatment in our previous report [19].
These results strongly indicate that CS had an inhibitory e¡ect
on something other than P450scc. It has been shown that
StAR protein plays an essential role in steroidogenesis
[2,3,30]. CS might also a¡ect StAR protein, a possibility
that warrants further investigation.
Moreover, it has been shown that there are at least seven
classes of chemical constituents of CS ^ proteins, polysaccha-
rides, sterols, nucleoside, fatty acids, vitamins, and inorganics
^ and that some of these components do have pharmacolog-
ical properties [5,16]. The peptide and carbohydrate moieties
of ligands play an important role in recognizing receptors that
activate signal pathways for various functions [31]. In the
present study, we found that CS could activate the cAMP^
PKA signal transduction pathway to regulate mouse Leydig
cell testosterone production. However, we cannot rule out the
possibility that di¡erent components of the polysaccharides
and/or glycoproteins in CS may also activate other pathways
to in£uence steroidogenesis. This might explain the 30% dif-
ference in the inhibitory e¡ects of forskolin-treated CS on
steroidogenesis and untreated CS on P450scc enzyme activity.
Thus, the search for the ¢ner components of CS that a¡ect
steroidogenesis and the involved signal pathways is worth
further investigation.
In conclusion, CS stimulated the cAMP^PKA signal trans-
duction pathway to regulate mouse Leydig cell testosterone
production. Moreover, the suppression of hCG-stimulated
testosterone production in mouse Leydig cells by CS might
be due to the CS-induced inhibition of P450scc enzyme activ-
ity.
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